Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) — The “Global Scopolamine Market” report has been added to ResearchAndMarkets.com’s offering.
The global scopolamine market is currently experiencing substantial growth and is projected to continue this ascent in the coming decade. This extensive research details the potential of the market through comprehensive analysis, offering crucial insights into factors influencing expansion.
According to the report, the market stood at an estimated USD 414.8 million in 2023 and is forecast to reach an impressive USD 772.9 million by 2034, accelerating at a Compound Annual Growth Rate (CAGR) of 5.91% over the forecast period of 2024-2034.
The surge in market size is attributed to escalating cases of motion sickness and Postoperative Nausea and Vomiting (PONV), augmented popularity and efficacy of transdermal patches, a rise in demand for minimally invasive surgical practices, and an increasing awareness of scopolamine in the management of Irritable Bowel Syndrome (IBS).
With transdermal patches taking the lead as the most revenue-generating segment, they demonstrate the growing inclination towards non-invasive and convenient drug delivery systems. These patches enable a steady and prolonged release of medication, thereby ensuring consistent levels of drug in the bloodstream and diminishing frequency of dosing.
The report also sheds light on the hospital pharmacies distribution channel which emerged as the highest revenue-grossing segment, highlighting the critical role these establishments play in the coordinated and effective delivery of healthcare treatments.
Segmentation: Scopolamine Market Report 2023 – 2034
- Injectables
- Tablets
- Transdermal Patches
- Others
From a regional perspective, North America is projected to hold the lion’s share of the market throughout the forecast period, whereas the Asia Pacific region is anticipated to experience the fastest growth, courtesy of improving healthcare infrastructures and the rising prevalence of relevant health conditions.
Geographically, the study extends its forecast across multiple key regions, offering valuable insights to stakeholders:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Points and Highlights of the Report:
- Insightful analysis on the market forecast by dosage form and distribution channel
- Comprehensive outlook for five regions and over 17 countries
- Exploration of the fast-growing online pharmacies segment due to consumer digital preferences
- In-depth company profiles of top players in the market
The extensive research accords an empirical approach to dissecting the industry dynamics, covering a 10-year horizon. It aims to assist stakeholders in mapping out their strategic positioning and tapping into the market’s burgeoning avenues, fully exploiting the wave of advancements set to revolutionize scopolamine treatment methodologies.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 – 2034 |
| Estimated Market Value (USD) in 2023 | $414.8 Million |
| Forecasted Market Value (USD) by 2034 | $772.9 Million |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
Companies Profiled
- Novartis AG
- Alkaloids Corporation
- Centroflora-CMS
- Fine Chemicals Corporation
- Phytex Australia
- Mylan N.V.
- Lannett Company Inc.
- Baxter International Inc.
- Perrigo Company plc
- Sandoz International GmbH (a division of Novartis)
- Alchem International Ltd.
- Acacia Pharma Group plc
- Alkaloida Chemical Company Zrt.
- Hi-Tech Pharmacal Co. Inc.
- CCM Duopharma Biotech Berhad
For more information about this report visit https://www.researchandmarkets.com/r/la1h96
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Global Scopolamine Market
